SENEX BIOTECHNOLOGY, INC.
Albany, NY · CIK 0001278295 · Biotech · Private
Small-molecule therapeutics targeting protein regulators of cancer cell adaptation and drug resistance
senexbio.com →- Grants
- $5.4M
- 10 awards
- Sector median: 1
- Raised
- $1.0M
- 3 Form D · Sep 2013
- 157 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 30
- 7 granted · 23 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20102012201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $200,000 | |
| Private capital raised | Form D · SEC | $400,000 | |
| Private capital raised | Form D · SEC | $426,079 | |
| Federal grant | Department of Health and Human Services · Phase I · CDK8/19 inhibitors for therapy of advanced prostate cancer | $240,750 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Enhancing cytarabine efficacy in leukemia through CDK inhibition | $299,891 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Enhancing cytarabine efficacy in leukemia through CDK8/19 inhibition | $299,891 | |
| Federal grant | Department of Health and Human Services · Phase I · CDK8/19 inhibitor for the treatment of HER2+ breast cancer | $299,993 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting CDK8 for the treatment of vein graft failure | $299,151 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting CDK for the treatment of vein graft failure | $299,151 | |
| Federal grant | Department of Health and Human Services · Phase II · CDK8/19 inhibitors for therapy of advanced prostate cancer | $1,977,275 | |
| Federal grant | Department of Health and Human Services · Phase II · CDK8/19 inhibitors for therapy of advanced prostate cancer | $846,340 | |
| Federal grant | Department of Health and Human Services · Phase I · Preventing in vivo resistance to PI3K/AKT/mTOR inhibitors through Mediator kinase inhibition | $400,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer | $400,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2566 | MUCOMMUNE, LLC | — | — |
| 2567 | Ichor Microbial Solutions, Inc. | — | $1.1M |
| 2568 | WAYPATH PHARMA LLC | — | — |
| 2569 | SENEX BIOTECHNOLOGY, INC. | — | $1.0M |
| 2570 | Decoy Therapeutics, Inc. | — | $1.0M |
| 2571 | NEW HORIZON BIOTECH INC | — | — |
| 2572 | AMPLION INC. | — | $1.0M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Richard DavidsonDirector
- Lawrence FriedhoffDirector · Executive Officer
- L MillerDirector
- Igor RoninsonDirector · Executive Officer
Patents
- Small-molecule Degraders Of CDK8 And CDK19application
- Quinoline-based Compounds And Methods Of Inhibiting CDK8/19granted
- CDK8/19 Inhibitors For Preventing Drug Resistanceapplication
- CDK8/19 Inhibitors For The Treatment Of Cytokine Stormapplication
- Bicyclic Pyridine Compositions And Methods Of Using The Same For Cancer Therapygranted
- 3-AMINO-4-[4-[4 (dimethylcarbamoyl) PHENYL]-1,4-DIAZEPAN-1-YL]THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE For Use In Cancer Therapy And Formulations Comprising The Sameapplication
- Suppression Of Neointimal Formation Following Vascular Surgeru Using CDK8 Inhibitorsapplication
- Quinoline-based Compounds And Methods Of Inhibiting CDK8/19granted
- CDK8-CDK19 Selective Inhibitors And Their Use In Anti-metastatic And Chemopreventative Methods For Cancergranted
- Cell-based Methods For Measuring Activity Of A Protein Inhibitorgranted
- TREATMENT OF DISEASES OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITYapplication
- Assay To Measure Efficacy Of CDK8/19 Inhibitorsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.